Swiss Federal Supreme Court to adopt EU SPC case law

Switzerland’s highest court held that new supplementary protection certificates (SPCs) for combination products should be governed by the relevant EU law, in a dispute over a Swiss SPC owned by Gilead Sciences.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

Swiss scientist convicted for GSK trade secrets theft

3 May 2022 A scientist working in Switzerland has been convicted of conspiring with his sister and others to steal trade secrets from GlaxoSmithKline for the benefit of their respective biopharmaceutical ventures.

Big Pharma

Swiss IP office issues SPC clarification

8 November 2018 The Swiss Federal Institute of Intellectual Property has issued a notice covering a change in the practice for granting supplementary protection certificates (SPCs), following a landmark decision by Switzerland’s highest court.

Big Pharma

AG opines on ‘thorny issue’ in Truvada SPC clash

25 April 2018 Advocate General Melchior Wathelet has advised the Court of Justice of the European Union on a case involving a supplementary protection certificate.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Swiss Federal Supreme Court to adopt EU SPC case law

More on this story

Editor's picks

Editor's picks

More features